Deadline: 15-Jul-2026
The Pfizer Independent Medical Education Grant Request for Proposals supports U.S.-based organizations developing medical education initiatives focused on improving diagnosis and treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Grants of up to $250,000 are available for one-year educational projects aimed at enhancing clinical knowledge, treatment strategies, and patient care outcomes in oncology practice.
What is the Pfizer Independent Medical Education Grant?
The Pfizer Independent Medical Education Grant is a competitive funding programme issued through internal review processes by Pfizer.
It supports independent educational initiatives focused on improving healthcare professional knowledge and clinical practice, particularly in oncology.
This specific RFP focuses on:
- ALK-positive metastatic non-small cell lung cancer (NSCLC)
- Clinical education for healthcare professionals
- Evidence-based treatment improvements
Purpose of the Program
The grant aims to:
- Improve clinical understanding of ALK-positive metastatic NSCLC
- Enhance awareness of updated clinical trial data
- Support better first-line and long-term treatment decisions
- Strengthen community oncology practice knowledge
- Improve patient care outcomes through education
Key Focus Areas
Clinical knowledge improvement
- Updated clinical data awareness
- Long-term outcomes in ALK-positive NSCLC
- Evidence-based oncology decision-making
Treatment optimization
- First-line therapy approaches
- Practical treatment management strategies
- Real-world oncology application
Healthcare professional education
- Community oncology education support
- Training for physicians, nurses, pharmacists, and allied health professionals
- Structured continuing education initiatives
Funding Details
- Maximum funding per project: $250,000
- Maximum duration: 1 year
- Type: Independent Medical Education (IME) grant
- Competitive review process under Pfizer internal evaluation
Eligible Applicants
Eligible organizations (U.S.-based only):
- Medical, nursing, pharmacy, or allied health professional schools
- Healthcare institutions
- Professional societies or medical associations
- Medical education companies
- Healthcare professional training organizations
- Other entities focused on medical education
Important requirements:
- Must be based in the United States
- Must act as project lead or authorized representative
- Must be capable of receiving funds directly from Pfizer
Accreditation Requirements
- Required if continuing education (CE/CME) credits are offered
- Must meet applicable accreditation standards for healthcare education
AI Disclosure Requirement
Applicants must:
- Disclose any use of artificial intelligence tools in proposal development
- Explain how AI tools were used
- Provide validation or verification processes for AI-generated content
What Types of Projects Are Supported?
The grant supports:
- Medical education programmes for oncology professionals
- Clinical training modules on ALK-positive NSCLC
- Continuing education workshops and seminars
- Digital or in-person healthcare training initiatives
- Evidence-based treatment guideline education
- Community oncology capacity-building programmes
How the Grant Works
- Eligible organizations design an educational proposal
- Application is submitted under Pfizer RFP guidelines
- Internal review and competitive evaluation by Pfizer
- Selected proposals receive funding (up to $250,000)
- Projects implemented within 12-month timeframe
- Outcomes focused on improved clinical knowledge and practice
Common Mistakes to Avoid
- Submitting proposals without clear oncology education focus
- Lack of alignment with ALK-positive NSCLC priorities
- Missing accreditation requirements (if CE credits included)
- Weak evaluation or outcome measurement plan
- Failure to disclose AI usage in proposal development
Tips for a Strong Application
- Focus on real-world clinical decision-making improvements
- Use up-to-date oncology research and evidence
- Target community oncology practice gaps
- Include measurable learning outcomes for clinicians
- Clearly define education delivery methods and evaluation metrics
- Ensure compliance with Pfizer RFP and accreditation rules
Frequently Asked Questions
- What is this Pfizer grant for?
- It supports medical education on ALK-positive metastatic NSCLC
- Focuses on improving clinical knowledge and treatment outcomes
- Who can apply?
- U.S.-based organizations only
- Includes hospitals, universities, medical societies, and education providers
- How much funding is available?
- Up to $250,000 per project
- Maximum duration of 1 year
- Can individuals apply?
- No
- Only organizations are eligible
- What is ALK-positive NSCLC?
- A subtype of non-small cell lung cancer driven by ALK gene alterations
- Is AI use allowed in applications?
- Yes, but must be fully disclosed with details of usage and validation
Conclusion
The Pfizer Independent Medical Education Grant programme supports structured oncology education initiatives that improve clinical understanding and management of ALK-positive metastatic NSCLC. By funding high-quality medical education projects, Pfizer aims to strengthen healthcare professional knowledge and ultimately improve patient outcomes in cancer care.
For more information, visit Pfizer.